The effect of vitamin B12 and folic acid supplementation on the treatment of multiple sclerosis

The effect of vitamin B12 and folic acid supplementation on serum homocysteine, megaloblastic anemia status, blood pressure and life quality in patients with multiple sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015100313678N7

Enrollment

Registered

2016-03-01

Start date

2016-02-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Folic acid 5mg oral supplement tablet once a day for intervention group. Intervention 2: Vitamin B12 1mg injective supplement. injecting 3 doses of it during the study period in the

Treatment - Drugs

Placebo

Folic acid 5mg oral supplement tablet once a day for intervention group

Vitamin B12 1mg injective supplement. injecting 3 doses of it during the study period in the intervention group. the first dose will be injected immediately after taking blood samples from the patie

Oral placebo tablets made of starch similar to folic acid once a day in the control group

normal saline injection similar to vitamin B12 intervention, injecting 3 doses of it during the study period in the intervention group. the first dose will be injected immediately after taking blood s

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with relapsing-remitting multiple sclerosis diagnosed with McDonald criteria; 20 to 40 age interval Exclusion criteria: other kind of neurological diseases or severe depression; kidney disorders; patients with traumatic brain injuries; cardiovascular disease; vitamin B6, vitamin B12, folic acid, choline or betaine consumption during the last six months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Life quality. Timepoint: Before and after the intervention. Method of measurement: MSQOL-54 standard questionnaire, persian edition.;Serum homocysteine. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Hemoglobin. Timepoint: Before and after the intervention. Method of measurement: Blood test.;MCV. Timepoint: Before and after the intervention. Method of measurement: Blood test.;MCHC. Timepoint: Before and after the intervention. Method of measurement: Blood test.	—

Measure

Time frame

Life quality. Timepoint: Before and after the intervention. Method of measurement: MSQOL-54 standard questionnaire, persian edition.;Serum homocysteine. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Hemoglobin. Timepoint: Before and after the intervention. Method of measurement: Blood test.;MCV. Timepoint: Before and after the intervention. Method of measurement: Blood test.;MCHC. Timepoint: Before and after the intervention. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 22, 2026